"Normal" is a dangerously imprecise word in laboratory medicine, conflating statistical, epidemiological, and clinical concepts into a single term that can mislead clinicians. In vitro diagnostic (IVD) manufacturers and assay developers must replace "normal values" and "normal ranges" with IFCC- and CLSI‑recommended terminology: reference individual, reference value, reference limits, and reference interval. This shift is far from cosmetic—it eliminates ambiguity, ensures clear clinical communication, and aligns technical documentation with modern regulatory expectations.
The ambiguity of “normal” springs from its simultaneous use to imply a Gaussian distribution, a common finding, or a disease‑free state—three meanings that rarely coincide. Diagnostic manufacturers should therefore adopt the precise IFCC/CLSI framework: a reference interval defines the central 95 % of values from a carefully characterized group of reference individuals, bounded by reference limits. Even with correct terminology, however, the intentionally broad intervals printed in package inserts cannot substitute for local, instrument‑specific verification—laboratories must establish their own target values to guard against subtle analytical errors.
Why “Normal” Has No Place in Modern IVD Documents
The Triple Meaning That Undermines Clarity
“Normal” can describe a Gaussian (bell‑shaped) distribution, a frequently observed result, or a clinically disease‑free state. These three meanings rarely align in practice.
A patient result may be statistically “normal” yet clinically pathological, or it may fall outside a Gaussian‑derived range while being a common, benign finding. Using a single overloaded term forces the interpreter to guess which meaning applies, jeopardizing diagnostic accuracy.
The Regulatory and Clinical Push for Precision
Global standards bodies like the IFCC and CLSI have long recommended abandoning “normal values” and “normal ranges.” Regulatory submissions that still use this language risk rejection or confusing reviewers.
Replacing the outdated words with standardized vocabulary makes it unmistakably clear what was measured, in whom, and how the boundaries were calculated. This precision is now a baseline expectation for any professional IVD technical document.
The IFCC/CLSI Terminology Framework
Starting with the Reference Individual
A reference individual is a subject selected using explicit, predefined criteria (e.g., age, sex, health status). The term replaces the vague “normal person” and forces the manufacturer to document exactly who was studied.
From Reference Value to Reference Limits
A reference value is the measurement obtained when you apply the assay to a reference individual. When the values from a well‑defined reference population are ordered, the reference limits are the lower and upper boundaries that capture a specified fraction—typically the central 95 %.
The Reference Interval as the Final Output
The reference interval is simply the span between the lower and upper reference limits. It is presented as a range (e.g., 4.0–10.5 ng/mL) and must always be accompanied by a description of the reference population and the statistical method used to derive the limits.
Common Pitfall: Trusting the Package‑Insert Reference Interval
Manufacturer Ranges Are Deliberately Broad
Even when manufacturers use the correct “reference interval” terminology, the ranges they place in the package insert are designed to cover variation across different instrument models, calibrator lots, and reagent lots in many laboratories. This intentional breadth makes the insert interval a screening benchmark, not a precision tool.
The Hidden Cost of Direct Application
Applying that pre‑assigned broad range directly in your laboratory dulls the diagnostic system’s sensitivity. It masks minor analytical shifts, emerging biases, or small calibration drifts that could otherwise be caught by a locally validated, instrument‑specific reference interval.
Why Local Verification Is Non‑Negotiable
To detect these subtle errors, each laboratory must establish localized target values and standard deviations derived from its own instrument and reagent performance under standard operating conditions. This isn’t a bureaucratic extra—it’s essential for maintaining result accuracy over time.
Actionable Steps for Diagnostic Manufacturers and Laboratories
How you act on the terminology change depends on your primary goal. The following recommendations translate the principles into concrete actions.
- If your primary focus is regulatory compliance: Replace every occurrence of “normal range” with “reference interval” and define the reference population from which it was derived, following CLSI EP28‑A3c guidelines.
- If your primary focus is kit validation and method comparison: Establish 95 % reference limits using a validated parametric or non‑parametric method (minimum 120 or 240 samples, respectively), report the standard error of the limits, and never rely solely on the insert interval.
- If your primary focus is ensuring accurate patient results over the assay’s lifetime: Educate end‑users that the package‑insert interval is a broad starting point; they must establish in‑house reference values with their own instrument and reagent lot, and regularly verify them through quality control to catch gradual analytical drifts.
By abandoning the ambiguous language of “normal” and coupling standardized terminology with rigorous local verification, you transform a source of confusion into a reliable tool for precise diagnosis.
Summary Table:
| Outdated Term | Recommended IFCC/CLSI Term | Definition / Clinical Purpose |
|---|---|---|
| Normal Person | Reference Individual | An individual selected using defined health and demographic criteria. |
| Normal Value | Reference Value | The specific test value obtained from a single reference individual. |
| Normal Range | Reference Interval | The central 95% span bounded by lower and upper reference limits. |
| Normal Limit | Reference Limit | The defined upper or lower boundary derived from the reference distribution. |
Upgrade Your Assay Performance with CamelBio
Transitioning to standard IFCC/CLSI reference terminology and ensuring rigorous assay verification requires absolute precision. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need robust raw materials or technical expertise for assay validation, we are here to support your success. Contact CamelBio Today to consult with our experts!